Protocol
Moxidectin in Onchocerciasis: Ongoing Clinical Trial Protocols 2
MDGH-MOX-3002: Safety of a single dose of moxidectin compared with ivermectin in individuals living in onchocerciasis-endemic areas. (Target: approx. 12,500 participants)
MDGH-MOX-3002: Safety of a single dose of moxidectin compared with ivermectin in individuals living in onchocerciasis-endemic areas. (Target: approx. 12,500 participants)
Stay up to date
Follow our work by signing up for our newsletter.
Search the site
MDGH respectfully acknowledges the Traditional Owners of the land on which our office is located, the Wurundjeri people of the Kulin Nation, and pay our respect to their Elders past, present and emerging.